BRCA1-deficient tumour cells are sensitive to poly(ADP-ribose) polymerase (PARP1) inhibitors (PARPi) through a mechanism of synthetic lethality, an interaction in which inhibition of PARP1 results in loss of cell viability specifically in cells deficient in HR (3, 4). Here, PARP1 is linked to neoplasm.